BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930-936. [PMID: 25096997 DOI: 10.1634/theoncologist.2014-0120] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Alexandraki KI, Angelousi A, Chatzellis E, Chrisoulidou A, Kalogeris N, Kanakis G, Savvidis C, Vassiliadi D, Spyroglou A, Kostopoulos G, Markussis V, Toulis K, Tsagarakis S, Kaltsas GA. The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis. J Pers Med 2023;13. [PMID: 36836538 DOI: 10.3390/jpm13020304] [Reference Citation Analysis]
2 Angelousi A, Koumarianou A, Chatzellis E, Kaltsas G. Resistance of neuroendocrine tumours to somatostatin analogs. Expert Rev Endocrinol Metab 2023;18:33-52. [PMID: 36651768 DOI: 10.1080/17446651.2023.2166488] [Reference Citation Analysis]
3 Hubbard JA, Wolfe RC. Management of Carcinoid Syndrome and Carcinoid Crisis in the Perioperative Environment. Journal of PeriAnesthesia Nursing 2022. [DOI: 10.1016/j.jopan.2022.08.016] [Reference Citation Analysis]
4 Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther 2022. [PMID: 36136274 DOI: 10.1007/s40487-022-00208-1] [Reference Citation Analysis]
5 Choi SI. Diagnosis and Treatment of Gastric Neuroendocrine Tumors. JDCR 2022;10:1-8. [DOI: 10.52927/jdcr.2022.10.1.1] [Reference Citation Analysis]
6 Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol 2022. [PMID: 35501552 DOI: 10.1007/s11864-022-00983-z] [Reference Citation Analysis]
7 Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 2021. [PMID: 34378163 DOI: 10.1007/s40273-021-01071-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Spyroglou A, Bramis K, Alexandraki KI. Neuroendocrine neoplasms: Evolving and future treatments. Current Opinion in Endocrine and Metabolic Research 2021;19:15-21. [DOI: 10.1016/j.coemr.2021.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 30.5] [Reference Citation Analysis]
10 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
11 Michael M, Chantrill L, Price T, Chan DL, Wakelin K, Cummins M. Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective. Asia Pac J Clin Oncol 2021;17 Suppl 2:3-10. [PMID: 33851520 DOI: 10.1111/ajco.13587] [Reference Citation Analysis]
12 Grimaldi F, Vescini F, Kara E. Treatment of NET-Related Symptoms. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_7] [Reference Citation Analysis]
13 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
14 Roberto GA, Rodrigues CMB, Peixoto RD, Younes RN. Gastric neuroendocrine tumor: A practical literature review. World J Gastrointest Oncol 2020; 12(8): 850-856 [PMID: 32879663 DOI: 10.4251/wjgo.v12.i8.850] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
15 Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Spada F, Maisonneuve P, Fumagalli C, Marconcini R, Gelsomino F, Antonuzzo L, Campana D, Puliafito I, Rossi G, Faviana P, Messerini L, Barberis M, Fazio N. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine 2021;72:268-78. [PMID: 32700133 DOI: 10.1007/s12020-020-02421-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Özdirik B, Tacke F, Benz F, Amthauer H, Fehrenbach U, Roderburg C, Jann H. A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. Medicine (Baltimore) 2020;99:e20820. [PMID: 32569231 DOI: 10.1097/MD.0000000000020820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019;26:R145-56. [PMID: 30608900 DOI: 10.1530/ERC-18-0495] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
19 Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Tsoli M, Alexandraki K, Xanthopoulos C, Kassi E, Kaltsas G. Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. Horm Metab Res. 2020;52:614-620. [PMID: 32108932 DOI: 10.1055/a-1110-7251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Jalbert JJ, Casciano R, Meng J, Brais LK, Pulgar SJ, Berthon A, Dinet J, Kulke MH. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center. Oncologist 2020;25:e644-50. [PMID: 31999024 DOI: 10.1634/theoncologist.2019-0691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Li Y, Xu J, Xu X, Zhang J, Zhang Y. Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors. Nuclear Medicine Communications 2019;40:1005-10. [DOI: 10.1097/mnm.0000000000001075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
24 Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
25 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Tsilimigras DI, Squires MH, Cloyd JM, Pawlik TM. Treatment strategies for neuroendocrine liver metastases: an update. Expert Opinion on Orphan Drugs 2019;7:327-35. [DOI: 10.1080/21678707.2019.1651639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20:70. [PMID: 31286272 DOI: 10.1007/s11864-019-0671-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
28 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
29 Daskalakis K, Tsoli M, Angelousi A, Kassi E, Alexandraki KI, Kolomodi D, Kaltsas G, Koumarianou A. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocr Connect. 2019;8:641-653. [PMID: 31026812 DOI: 10.1530/ec-19-0134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
31 Clement DS, Tesselaar ME, van Leerdam ME, Srirajaskanthan R, Ramage JK. Nutritional and vitamin status in patients with neuroendocrine neoplasms. World J Gastroenterol 2019; 25(10): 1171-1184 [PMID: 30886501 DOI: 10.3748/wjg.v25.i10.1171] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
32 Hofland J, Herrera-martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocrine-Related Cancer 2019;26:R145-56. [DOI: 10.1530/erc-18-0495] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
34 Tsoli M, Kaltsas G. Carcinoid Syndrome. Encyclopedia of Endocrine Diseases 2019. [DOI: 10.1016/b978-0-12-801238-3.65346-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Cives M, Pellè E, Silvestris F, Strosberg J. Management of NETs in the Precision Medicine Era. Oncogenomics 2019. [DOI: 10.1016/b978-0-12-811785-9.00041-7] [Reference Citation Analysis]
36 Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol 2018;53:1509-18. [PMID: 30449217 DOI: 10.1080/00365521.2018.1531653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
37 Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther 2018;40:2006-2020.e2. [PMID: 30477789 DOI: 10.1016/j.clinthera.2018.10.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
38 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
39 Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians 2018;68:471-87. [DOI: 10.3322/caac.21493] [Cited by in Crossref: 209] [Cited by in F6Publishing: 235] [Article Influence: 41.8] [Reference Citation Analysis]
40 de Herder WW. When and How to Use Somatostatin Analogues. Endocrinology and Metabolism Clinics of North America 2018;47:549-55. [DOI: 10.1016/j.ecl.2018.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
41 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
42 Burton T, Lapuerta P. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. Future Oncol. 2018;14:2361-2370. [PMID: 30095284 DOI: 10.2217/fon-2018-0129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
43 Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
44 Lamarca A, McCallum L, Nuttall C, Barriuso J, Backen A, Frizziero M, Leon R, Mansoor W, McNamara MG, Hubner RA, Valle JW. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Rev Gastroenterol Hepatol 2018;12:723-31. [PMID: 29923433 DOI: 10.1080/17474124.2018.1489232] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
45 Kaltsas G, I. Alexandraki K, Grossman AB. Acute Endocrine and Metabolic Emergencies Related to Neuroendocrine Tumors. Endocrine and Metabolic Medical Emergencies 2018. [DOI: 10.1002/9781119374800.ch29] [Reference Citation Analysis]
46 Öberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg 2018;7:20-7. [PMID: 29629316 DOI: 10.21037/gs.2017.10.08] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
47 Chan DL, Segelov E, Singh S. Therapy for Metastatic Disease: Ileum. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_22] [Reference Citation Analysis]
48 Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics. 2017;11:115-122. [PMID: 29255345 DOI: 10.2147/btt.s108818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
49 Joish VN, Frech F, Lapuerta P. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clin Ther 2017;39:2338-44. [PMID: 29175096 DOI: 10.1016/j.clinthera.2017.10.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
50 Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
51 Cives M, Pellè E, Silvestris F. The management of refractory carcinoid syndrome: challenges and opportunities ahead. J Med Econ 2018;21:241-3. [PMID: 29039712 DOI: 10.1080/13696998.2017.1394312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Huguet I, Grossman A. MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts. Eur J Endocrinol 2017;177:R219-29. [PMID: 28982960 DOI: 10.1530/EJE-17-0295] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Capdevila J, López C, Teule A, Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE). Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2017;19:72. [PMID: 28920153 DOI: 10.1007/s11912-017-0633-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
54 Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res 2017;9:495-503. [PMID: 28860831 DOI: 10.2147/CEOR.S140866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
55 Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Curr Treat Options Oncol 2017;18:14. [PMID: 28286921 DOI: 10.1007/s11864-017-0461-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
56 Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol 2016;28:359-66. [PMID: 27138571 DOI: 10.1097/CCO.0000000000000299] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
57 Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57:366-375. [PMID: 28726183 DOI: 10.1007/s12020-017-1360-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
58 Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics 2017;20:945-51. [DOI: 10.1080/13696998.2017.1337019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105:266-280. [PMID: 28351033 DOI: 10.1159/000471880] [Cited by in Crossref: 98] [Cited by in F6Publishing: 101] [Article Influence: 16.3] [Reference Citation Analysis]
60 Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016;17:2487-2498. [PMID: 27817224 DOI: 10.1080/14656566.2016.1254191] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
61 Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: A review of treatment options. Ther Adv Med Oncol. 2017;9:127-137. [PMID: 28203303 DOI: 10.1177/1758834016675803] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
62 Chung C. Management of neuroendocrine tumors. American Journal of Health-System Pharmacy 2016;73:1729-44. [DOI: 10.2146/ajhp150373] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
63 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
64 Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:163-77. [PMID: 26614375 DOI: 10.1016/j.hoc.2015.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
65 Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23:R423-R436. [PMID: 27461388 DOI: 10.1530/erc-16-0200] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
66 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, ELECT Study Group *. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22:1068-1080. [PMID: 27214300 DOI: 10.4158/ep151172.or] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 9.0] [Reference Citation Analysis]
68 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
69 Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 2016;3:175-89. [PMID: 27347369 DOI: 10.2217/ije-2015-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
70 Viúdez A, De Jesus-Acosta A, Carvalho FL, Vera R, Martín-Algarra S, Ramírez N. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. Crit Rev Oncol Hematol 2016;101:193-206. [PMID: 27021395 DOI: 10.1016/j.critrevonc.2016.03.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
71 Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016;21:308-313. [PMID: 26911407 DOI: 10.1634/theoncologist.2015-0381] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
72 Marquez-medina D, Popat S. Systemic therapy for pulmonary carcinoids. Lung Cancer 2015;90:139-47. [DOI: 10.1016/j.lungcan.2015.08.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
73 Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855-1863. [PMID: 25918282 DOI: 10.1200/jco.2014.60.2532] [Cited by in Crossref: 99] [Cited by in F6Publishing: 105] [Article Influence: 12.4] [Reference Citation Analysis]
74 Cives M, Strosberg J. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 2015;75:847-58. [DOI: 10.1007/s40265-015-0397-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
75 Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med 2015;4:864-70. [PMID: 25727756 DOI: 10.1002/cam4.435] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]